التفاصيل البيبلوغرافية
| العنوان: |
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia |
| المؤلفون: |
Stein, Andrew M, Martinelli, Giovanni, Hughes, Timothy P, Müller, Martin C, Beppu, Lan, Gottardi, Enrico, Branford, Susan, Soverini, Simona, Woodman, Richard C, Hochhaus, Andreas, Kim, Dong-Wook, Saglio, Giuseppe, Radich, Jerald P |
| بيانات النشر: |
BioMed Central Ltd. |
| سنة النشر: |
2013 |
| المجموعة: |
BioMed Central |
| مصطلحات موضوعية: |
Chronic myeloid leukemia, Nilotinib, Mathematical modeling, BCR-ABL, Molecular response |
| الوصف: |
Background We evaluated BCR-ABL1 kinetics in patients treated with nilotinib and analyzed whether a dynamic model of changes in BCR-ABL1 levels over time could be used to predict long-term responses. Methods Patients from the nilotinib registration trial (CAMN107A2101; registered at http://www.clinicaltrials.govTest as NCT00109707 ) who had imatinib-resistant or -intolerant Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) or accelerated phase with BCR-ABL1 > 10% (on the international scale [IS]) at baseline and, in the first 6 months, had at least three BCR-ABL1 transcript measurements and an average daily dose of at least 720 mg were included in this analysis (N = 123). Results More than half of patients (65/123; 53%) had a slow monophasic response and the remainder (58/123; 47%) had a biphasic response, in which patients had a rapid initial decrease in BCR-ABL1 transcripts followed by a more gradual response. The biphasic response type strongly correlated with improved event-free survival (EFS). Data in the first 6 months of follow-up were sufficient to predict EFS at 24 months. Conclusions Unlike newly diagnosed patients with Ph+ CML-CP—in whom the majority had a biphasic response—approximately half of patients with imatinib-resistant or -intolerant CML had a slower, monophasic response. Second-line patients who did have a biphasic response had an EFS outlook similar to that of newly diagnosed patients treated with imatinib. Our model was comparable to using BCR-ABL1 (IS) ≤ 10% at 6 months as a threshold for predicting EFS. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| العلاقة: |
http://www.biomedcentral.com/1471-2407/13/173Test |
| الإتاحة: |
http://www.biomedcentral.com/1471-2407/13/173Test |
| حقوق: |
Copyright 2013 Stein et al.; licensee BioMed Central Ltd. |
| رقم الانضمام: |
edsbas.4FA1E310 |
| قاعدة البيانات: |
BASE |
